Correlation between ETFDH mutations and dysregulation of serum myomiRs in MADD patients


Submitted: 5 February 2020
Accepted: 15 February 2020
Published: 1 April 2020
Abstract Views: 826
PDF: 518
HTML: 16
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Sara Missaglia Laboratory of Cellular Biochemistry and Molecular Biology, CRIBENS, Università Cattolica del Sacro Cuore, Milan; Department of Psychology, Università Cattolica del Sacro Cuore, Milan, Italy.
  • Valentina Pegoraro IRCCS San Camillo Hospital, Venice, Italy.
  • Roberta Marozzo IRCCS San Camillo Hospital, Venice, Italy.
  • Daniela Tavian Laboratory of Cellular Biochemistry and Molecular Biology, CRIBENS, Università Cattolica del Sacro Cuore, Milan; Department of Psychology, Università Cattolica del Sacro Cuore, Milan, Italy.
  • Corrado Angelini IRCCS San Camillo Hospital, Venice, Italy.

Multiple acyl-CoA dehydrogenase deficiency (MADD) is a rare fatty acids oxidation disorder which is often associated with deficiency of electron transfer flavoprotein dehydrogenase (ETFDH). In this study we reported clinical features and evaluation of expression profile of circulating muscle-specific miRNAs (myomiRs) in two MADD patients carrying different ETFDH gene mutations. Patient 1 was a compound heterozygote for two missense mutations. She showed a late onset MADD clinical phenotype and a significant increase of serum myomiRs. Patient 2, carrying a missense and a frameshift mutation, displayed early onset symptoms and a slight increase of some serum myomiRs.


Merritt JL 2nd, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med 2018;6:473. DOI: https://doi.org/10.21037/atm.2018.10.57

Angelini C, Pennisi E, Missaglia S, et al. Metabolic lipid muscle disorders: biomarkers and treatment. Ther Adv Neurol Disord 2019;12:1756286419843359. DOI: https://doi.org/10.1177/1756286419843359

Zhang J, Frerman FE, Kim JJ. Structure of electron transfer flavoprotein-ubiquinone oxidoreductase and electron transfer to the mitochondrial ubiquinone pool. Proc Natl Acad Sci U S A 2006;103:16212–16217. DOI: https://doi.org/10.1073/pnas.0604567103

Grunert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme a dehydrogenase deficiency. Orphanet J Rare Dis 2014;9:117. DOI: https://doi.org/10.1186/s13023-014-0117-5

Bhaskaran M, Mohan M. MicroRNAs: History, Biogenesis, and Their Evolving Role in Animal Development and Disease. Vet Pathol 2014;5:759-774. DOI: https://doi.org/10.1177/0300985813502820

Siracusa J, Koulmann N, Banzet S. Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine. J Cachexia Sarcopenia Muscle 2018;9:20‐27. DOI: https://doi.org/10.1002/jcsm.12227

Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoprotein. Nat Cell Biol 2011;13:423-433. DOI: https://doi.org/10.1038/ncb2210

Horak M, Novak J, Bienertova-Vasku J. Muscle-specific microRNAs in skeletal muscle development. Dev Biol 2016;410:1–13. DOI: https://doi.org/10.1016/j.ydbio.2015.12.013

Mitchelson KR, Qin WY. Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease. World J Biol Chem 2015;6:162–208. DOI: https://doi.org/10.4331/wjbc.v6.i3.162

Cacchiarelli D, Legnini I, Martone J, et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 2011;3:258‐265. DOI: https://doi.org/10.1002/emmm.201100133

Pegoraro V, Missaglia S, Marozzo R, et al. MiRNAs as biomarkers of phenotype in neutral lipid storage disease with myopathy. Muscle Nerve 2020;61:253-257. DOI: https://doi.org/10.1002/mus.26761

Angelini C, Tavian D, Missaglia S. Heterogeneous Phenotypes in Lipid Storage Myopathy Due to ETFDH Gene Mutations. JIMD Rep. 2018;38:33-40. DOI: https://doi.org/10.1007/8904_2017_27

Missaglia S, Tavian D, Moro L, et al. Characterization of two ETFDH mutations in a novel case of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Lipids Health Dis 2018;17:254. DOI: https://doi.org/10.1186/s12944-018-0903-5

Townley-Tilson WHD, Callis TE, Wang D. MicroRNAs 1, 133, and 206: Critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 2010;42:1252–1255 DOI: https://doi.org/10.1016/j.biocel.2009.03.002

Missaglia, S., Pegoraro, V., Marozzo, R., Tavian, D., & Angelini, C. (2020). Correlation between ETFDH mutations and dysregulation of serum myomiRs in MADD patients. European Journal of Translational Myology, 30(1), 116–120. https://doi.org/10.4081/ejtm.2019.8880

Downloads

Download data is not yet available.

Citations